How to appeal a Blue Cross Blue Shield of Massachusetts melanoma & melanoma-immunotherapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Massachusetts-specific note: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.

What Blue Cross Blue Shield of Massachusetts's policy requires for melanoma & melanoma-immunotherapy

Cited policy: BCBS Kimmtrak (Tebentafusp-tebn) for Uveal Melanoma

HLA-A*02:01-positive (must submit HLA typing report) metastatic or unresectable uveal melanoma. Age ≥18. ECOG 0-1. Inpatient or monitored outpatient first 3 doses (cytokine release syndrome monitoring). Step-up dosing weekly: 20 mcg → 30 mcg → 68 mcg.

How Blue Cross Blue Shield of Massachusetts denies melanoma & melanoma-immunotherapy — and how to counter it

Where Blue Cross Blue Shield of Massachusetts pushes back: 1) HLA typing not documented; 2) Uveal melanoma 'rare — try systemic ICI first'; 3) Site-of-care monitoring requirements not met.

Counter-arguments that hold up: FDA Jan 25, 2022 — first and only FDA-approved therapy with OS benefit in metastatic uveal melanoma. IMCgp100-202 (Nathan NEJM 2021; Hassel NEJM 2023 3-yr): OS HR 0.51 vs investigator's choice (incl. dacarbazine/Yervoy/Keytruda). Cutaneous-melanoma checkpoint inhibitors do NOT show OS benefit in uveal — uveal has low TMB, distinct biology. Submit HLA-A*02:01 typing + step-up dosing protocol; CRS monitoring per FDA REMS.

What Blue Cross Blue Shield of Massachusetts typically denies for melanoma & melanoma-immunotherapy

Across Blue Cross Blue Shield of Massachusetts's commercial and Medicare books, denials cluster around a small number of patterns. For melanoma & melanoma-immunotherapy, expect:

• MA-specific mandated benefit disputes (most generous in US)
• Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
• Tiered-network provider disputes
• Specialty drug PA

Treatments most often denied in this category

These are the melanoma & melanoma-immunotherapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Keytruda (pembrolizumab)
• Opdivo (nivolumab) mono
• Yervoy (ipilimumab)
• Opdivo + Yervoy combo
• Opdualag (nivo+rela)
• Tafinlar + Mekinist

How to submit the appeal to Blue Cross Blue Shield of Massachusetts

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Massachusetts cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Massachusetts's portal (members: https://home.bluecrossma.com ; providers: https://provider.bluecrossma.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Massachusetts's prior-authorization criteria by drug: Blue Cross Blue Shield of Massachusetts PA criteria on ApprovalHelp.